表紙
市場調查報告書

熱門市場分析:甲狀腺癌

Market Spotlight: Thyroid Cancer

出版商 Datamonitor Healthcare 商品編碼 594583
出版日期 內容資訊 英文 47 Pages
商品交期: 最快1-2個工作天內
價格
熱門市場分析:甲狀腺癌 Market Spotlight: Thyroid Cancer
出版日期: 2019年11月26日內容資訊: 英文 47 Pages
簡介

本報告提供甲狀腺癌治療的市場相關分析,提供疾病概要和患者數的轉變·預測,目前的主要治療方法及臨床實驗·認證情形,甲狀腺癌治療市場趨勢預測 (今後10年份),資本交易的動向,現在開發中臨床實驗的進展等調查。

分析的要點

疾病的背景情況

  • 甲狀腺癌的種類

治療方法

  • 手術
  • 放射線碘 (RAI) 療法
  • 甲狀腺荷爾蒙療法
  • 體外放射治療
  • 標靶治療

流行病學

已上市醫藥品

開發平台上的醫藥品

今後的市場主要動向

授權合約·資產收購交易 (1件)

母體專利

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各期

相關分析

  • 處方藥的資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0182051

This Market Spotlight report covers the thyroid cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and five-year prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 559,800 incident cases of thyroid cancer worldwide, and expects that number to increase to 612,600 incident cases by

2026. In the same year, there were an estimated 2.0 million five-year prevalent cases of thyroid cancer worldwide, which is expected to increase to 2.2 million cases by

2026. The approved drugs in the thyroid cancer space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with one product being available in an intramuscular formulation.

There are only five industry-sponsored drugs in active clinical development for thyroid cancer, with three drugs in Phase II and two in Phase I.

Therapies in early-to-mid-stage development for thyroid cancer focus on targets such as RET, carcinoembryonic antigen, immune system, tumor necrosis factor-alpha, and ErbB3/HER3. These therapies are administered via the oral, intravenous, and subcutaneous routes.

The release of topline Phase II trial results for GI-6207 is the only high-impact upcoming event in the thyroid cancer space. The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 41%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been 13 licensing and asset acquisition deals involving thyroid cancer drugs during 2014-19. The $1,550m exclusive global collaboration signed in November 2017 between Bayer and Loxo Oncology for the development and commercialization of two novel oncology therapies selectively targeting genetic drivers of cancer was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for thyroid cancer have been in the early and mid-phases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.

The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.

Clinical trial activity in the thyroid cancer space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for thyroid cancer, with 33 trials.

Novartis leads industry sponsors with the highest overall number of clinical trials for thyroid cancer, followed by Pfizer.

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

8 Subtypes

10 TREATMENT

10 Surgery

10 Radioactive iodine (RAI) therapy

10 Thyroid hormone therapy

10 External beam radiation therapy

11 Targeted therapy

12 EPIDEMIOLOGY

16 MARKETED DRUGS

19 PIPELINE DRUGS

23 RECENT EVENTS AND ANALYST OPINION

23 Selpercatinib for Thyroid Cancer (September 29, 2019)

24 BLU-667 for Thyroid Cancer (June 3, 2019)

26 BLU-667 for Thyroid Cancer (May 15, 2019)

27 Selumetinib for Thyroid Cancer (July 26, 2018)

29 Selumetinib for Thyroid Cancer (June 2, 2018)

32 KEY UPCOMING EVENTS

33 PROBABILITY OF SUCCESS

34 LICENSING AND ASSET ACQUISITION DEALS

34 Lift-Off For Lilly In Cancer Genetics With Loxo Buy

36 PARENT PATENTS

37 REVENUE OPPORTUNITY

38 CLINICAL TRIAL LANDSCAPE

39 Sponsors by status

40 Sponsors by phase

41 Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib

42 BIBLIOGRAPHY

42 Prescription information

44 APPENDIX

LIST OF FIGURES

  • 14 Figure 1: Trends in incident cases of thyroid cancer, 2017-26
  • 19 Figure 2: Overview of pipeline drugs for thyroid cancer in the US
  • 19 Figure 3: Pipeline drugs for thyroid cancer, by company
  • 20 Figure 4: Pipeline drugs for thyroid cancer, by drug type
  • 20 Figure 5: Pipeline drugs for thyroid cancer, by classification
  • 24 Figure 6: Selpercatinib for Thyroid Cancer (September 29, 2019): Phase I/II - LIBRETTO-001
  • 26 Figure 7: BLU-667 for Thyroid Cancer (June 3, 2019): Phase I - ARROW (NSCLC, Thyroid, Solids)
  • 27 Figure 8: BLU-667 for Thyroid Cancer (May 15, 2019): Phase I - ARROW (NSCLC, Thyroid, Solids)
  • 29 Figure 9: Selumetinib for Thyroid Cancer (July 26, 2018): Phase III - ASTRA
  • 31 Figure 10: Selumetinib for Thyroid Cancer (June 2, 2018): Phase I/II - LIBRETTO-001
  • 32 Figure 11: Key upcoming events in thyroid cancer
  • 33 Figure 12: Probability of success in the thyroid cancer pipeline
  • 34 Figure 13: Licensing and asset acquisition deals in thyroid cancer, 2014-19
  • 36 Figure 14: Parent patents in thyroid cancer
  • 38 Figure 15: Clinical trials in thyroid cancer
  • 38 Figure 16: Top 10 drugs for clinical trials in thyroid cancer
  • 39 Figure 17: Top 10 companies for clinical trials in thyroid cancer
  • 39 Figure 18: Trial locations in thyroid cancer
  • 40 Figure 19: Thyroid cancer trials status
  • 41 Figure 20: Thyroid cancer sponsors, by phase

LIST OF TABLES

  • 13 Table 1: Incident cases of thyroid cancer, 2017-26
  • 15 Table 2: Five-year prevalent cases of thyroid cancer, 2017-26
  • 17 Table 3: Marketed drugs for thyroid cancer
  • 21 Table 4: Pipeline drugs for thyroid cancer in the US
  • 23 Table 5: Selpercatinib for Thyroid Cancer (September 29, 2019)
  • 25 Table 6: BLU-667 for Thyroid Cancer (June 3, 2019)
  • 26 Table 7: BLU-667 for Thyroid Cancer (May 15, 2019)
  • 28 Table 8: Selumetinib for Thyroid Cancer (July 26, 2018)
  • 29 Table 9: Selumetinib for Thyroid Cancer (June 2, 2018)
  • 37 Table 10: Historical global sales, by drug ($m), 2014-18
  • 37 Table 11: Forecasted global sales, by drug ($m), 2019-23